Phosplatin Therapeutics Announces First Patients Enrolled In Phase I First-in-Human Clinical Trial In Solid Tumors
NEW YORK--(BUSINESS WIRE)--Phosplatin Therapeutics LLC today announced that the first cohort of patients has been successfully dosed in its Phase I first-in-human clinical study of PT-112, the lead therapeutic candidate among its phosphaplatin family of molecules.
The clinical study is expected to enroll up to 80 patients across three sites: The University of Texas MD Anderson Cancer Center in Houston, Texas; the Sarah Cannon Research Institute in Nashville, Tennessee; and the University of Colorado Cancer Center in Aurora, Colorado. The study will consist of two parts: a dose escalation portion to assess the safety, pharmacokinetic behavior and maximum tolerated dose of PT-112 in an open label setting of solid tumor cancer patients; and a subsequent dose confirmation portion to consider PT-112’s activity in discreet cohorts of patients with specific disease characteristics.
According to Principal Investigator Daniel Karp, M.D., Professor of Investigational Cancer Therapeutics, and Medical Director of the Clinical Translational Research Center at MD Anderson, “The platinum family of chemotherapies has been a bedrock contributor to long-term survival of cancer patients, and remains so today, even in our world of targeted therapies.” He added that, “We are delighted to be involved in this important study of PT-112.”
Phosplatin Therapeutics’ CEO, Robert E. Fallon, commented: “For a small company like ours it is both encouraging, and testimony to the therapeutic potential of our compound, that we have been able to line up a top-tier group of clinical sites and investigators to lead the first trial of PT-112 in humans.”
Dr. Karp is a funded Principal Investigator on the PT-112 research protocol, and has not received any personal compensation for this work.
About PT-112
PT-112 is a novel molecule, a member of the phosphaplatin family of compounds that were first synthesized by Rathindra N. Bose, PhD, Chairman of the Phosplatin Therapeutics Scientific Advisory Board.
When compared to prior members of the platinum therapeutic class in pre-clinical studies, PT-112’s unique electrochemistry and plasma stability engendered improved tolerability and safety, and proved highly efficacious in several mouse models using patient-derived tumors.
More information about the study for patients or physicians can be found via the following link: http://clinicaltrials.gov/show/NCT02266745
About Phosplatin Therapeutics
Phosplatin Therapeutics is a private pharmaceutical development company engaged in the development of phosphaplatins, a novel class of chemotherapeutic compounds. The company’s work to date has been funded by private investors, with research initiatives in the United States, Europe and Asia. The company continues to work closely on regulatory and clinical activities with Accellient Partners LLC of Waltham, Massachusetts.
Contacts
Phosplatin Therapeutics LLC
Naveen Bazaj, 646-380-2441
info@phosplatin.com
Help employers find you! Check out all the jobs and post your resume.
The clinical study is expected to enroll up to 80 patients across three sites: The University of Texas MD Anderson Cancer Center in Houston, Texas; the Sarah Cannon Research Institute in Nashville, Tennessee; and the University of Colorado Cancer Center in Aurora, Colorado. The study will consist of two parts: a dose escalation portion to assess the safety, pharmacokinetic behavior and maximum tolerated dose of PT-112 in an open label setting of solid tumor cancer patients; and a subsequent dose confirmation portion to consider PT-112’s activity in discreet cohorts of patients with specific disease characteristics.
According to Principal Investigator Daniel Karp, M.D., Professor of Investigational Cancer Therapeutics, and Medical Director of the Clinical Translational Research Center at MD Anderson, “The platinum family of chemotherapies has been a bedrock contributor to long-term survival of cancer patients, and remains so today, even in our world of targeted therapies.” He added that, “We are delighted to be involved in this important study of PT-112.”
Phosplatin Therapeutics’ CEO, Robert E. Fallon, commented: “For a small company like ours it is both encouraging, and testimony to the therapeutic potential of our compound, that we have been able to line up a top-tier group of clinical sites and investigators to lead the first trial of PT-112 in humans.”
Dr. Karp is a funded Principal Investigator on the PT-112 research protocol, and has not received any personal compensation for this work.
About PT-112
PT-112 is a novel molecule, a member of the phosphaplatin family of compounds that were first synthesized by Rathindra N. Bose, PhD, Chairman of the Phosplatin Therapeutics Scientific Advisory Board.
When compared to prior members of the platinum therapeutic class in pre-clinical studies, PT-112’s unique electrochemistry and plasma stability engendered improved tolerability and safety, and proved highly efficacious in several mouse models using patient-derived tumors.
More information about the study for patients or physicians can be found via the following link: http://clinicaltrials.gov/show/NCT02266745
About Phosplatin Therapeutics
Phosplatin Therapeutics is a private pharmaceutical development company engaged in the development of phosphaplatins, a novel class of chemotherapeutic compounds. The company’s work to date has been funded by private investors, with research initiatives in the United States, Europe and Asia. The company continues to work closely on regulatory and clinical activities with Accellient Partners LLC of Waltham, Massachusetts.
Contacts
Phosplatin Therapeutics LLC
Naveen Bazaj, 646-380-2441
info@phosplatin.com
Help employers find you! Check out all the jobs and post your resume.